“The company will need to send the protection data, evaluated through the Data Security Monitoring Board (DSMB), to CDSCO before conducting phase 3 clinical trials,” a senior official told the PTI news agency.
Officials said the IRS submitted a revised proposal Wednesday after Tuesday’s panel asked it to review its protocol for Phase II and III trials.
The organization recommended that human control sites for examination be distributed throughout the country. Approximately 1,600 other people will participate in the clinical trial. Volunteers must be 18 years of age or older to participate in the exam. Serum Institute has decided 17 establishments to conduct complex trials. These sites are AIIMS-Delhi, BJ Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.
“Depending on the design of the study, the topic will be given two doses over a 4-week period (first dose on the first day and dose at the time on day 29), after which protection and immunogenicity will be evaluated at predefined periods,” the official told PTI.
“According to the request, a randomized controlled blind examination of observers would be conducted for the protection and immunogenicity of ‘Covishield’ in healthy Indian adults,” the official said, according to THE PTI.
The COVID-19 candidate vaccine evolved through the University of Oxford and the Anglo-Swedish company AstraZeneca. Phase II and II clinical trials of the Oxford candidate vaccine in the UK, a Phase II clinical trial in Brazil and Phase I and II clinical trials in South Africa are currently underway. AstraZeneca has partnered with IBS to expand the COVID-19 vaccine for India and low- to middle-income countries.
All eyes are on the Oxford coronavirus vaccine, as it has already shown promising effects in the first phase of the human clinical trial. Researchers reported that they found that their experimental COVID-19 vaccine produced a double immune reaction in others over the age of 18 to 55. “We’re seeing a smart immune reaction in almost everyone,” said Dr Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does well is cause any of the arms of the immune system,” he said.
Indian drug manufacturer Wockhardt Ltd will supply millions of doses of several COVID-19 vaccines to the UK, adding one developed through AstraZeneca and Oxford University, he said. The company has reserved a filling and filling capacity, the final production level of putting vaccines in vials or syringes and packaging them, as a component of an agreement with the UK government, he said.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.